VA
CLBT icon

Vident Advisory’s Cellebrite CLBT Stock Holding History

Vident Advisory’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$919K Buy
62,914
+6,693
+12% +$88.5K 0.01% 1018
2026
Q1 		$775K Buy
56,221
+5,334
+10% +$80.4K 0.01% 995
2025
Q4 		$917K Buy
50,887
+3,372
+7% +$60.5K 0.01% 846
2025
Q3 		$880K Buy
+47,515
New +$746K 0.01% 889

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Vident Advisory's CLBT Position: Q2 2026 in Review

Vident Advisory increased its Cellebrite (CLBT) stake by 12% in Q2 2026, buying an estimated $88.5K and bringing the position to 62,914 shares worth $919K. The position accounts for 0.01% of the portfolio, ranked #1018.

Vident Advisory first reported a position in CLBT in Q3 2025 and has held it in 4 quarters since. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Vident Advisory held 62,914 shares of Cellebrite worth $919K as of Q2 2026.
  • Vident Advisory bought 6,693 Cellebrite shares in Q2 2026, an estimated $88.5K.
  • Cellebrite made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1018 holding.
  • Vident Advisory first reported a position in Cellebrite in Q3 2025 and has held it in 4 quarters since.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.